化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Chemotherapy Induced Neutropenia - Pipeline Review, H2 2014
◆商品コード:GMDHC5798IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月30日
◆ページ数:105
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia)の概要
・化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Chemotherapy Induced Neutropenia – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Chemotherapy Induced Neutropenia – Pipeline Review, H2 2014’, provides an overview of the Chemotherapy Induced Neutropenia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Neutropenia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chemotherapy Induced Neutropenia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chemotherapy Induced Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chemotherapy Induced Neutropenia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Chemotherapy Induced Neutropenia Overview 10
Therapeutics Development 11
Pipeline Products for Chemotherapy Induced Neutropenia – Overview 11
Pipeline Products for Chemotherapy Induced Neutropenia – Comparative Analysis 12
Chemotherapy Induced Neutropenia – Therapeutics under Development by Companies 13
Chemotherapy Induced Neutropenia – Therapeutics under Investigation by Universities/Institutes 16
Chemotherapy Induced Neutropenia – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Chemotherapy Induced Neutropenia – Products under Development by Companies 21
Chemotherapy Induced Neutropenia – Products under Investigation by Universities/Institutes 23
Chemotherapy Induced Neutropenia – Companies Involved in Therapeutics Development 24
Bio-Ker s.r.l 24
Biogenomics Limited 25
Bolder Biotechnology, Inc. 26
Cellerant Therapeutics, Inc. 27
Dong-A Socio Group 28
Generon (Shanghai) Corporation Ltd. 29
Hanmi Pharmaceuticals, Co. Ltd. 30
Io Therapeutics, Inc. 31
Jiangsu Hengrui Medicine Co., Ltd. 32
Mycenax Biotech Inc. 33
Myelo Therapeutics GmbH 34
Octapharma AG 35
PharmaEssentia Corporation 36
Reliance Life Sciences Pvt. Ltd. 37
Richter Gedeon Nyrt. 38
Sandoz Inc. 39
Teva Pharmaceutical Industries Limited 40
UAB Profarma 41
USV Limited 42
Welichem Biotech Inc. 43
XBiotech USA, Inc. 44
Chemotherapy Induced Neutropenia – Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Target 46
Assessment by Mechanism of Action 48
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
balugrastim – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
BBT-007 – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
BBT-015 – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
BBT-018 – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
BK-0026 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Cell Therapy for Chemotherapy Induced Neutropenia – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
F-627 – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
filgrastim – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
filgrastim – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
filgrastim – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
filgrastim – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
filgrastim – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
filgrastim – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
filgrastim – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
filgrastim (recombinant) – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
GW-003 – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
HM-10460A – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
IRX-4310 – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
lipegfilgrastim – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Myelo-001 – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
pegfilgrastim – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
pegfilgrastim – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
pegfilgrastim – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
pegfilgrastim – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
pegfilgrastim – Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
pegfilgrastim – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
pegfilgrastim – Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
pegfilgrastim – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
pegfilgrastim – Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Recombinant Protein for Chemotherapy Induced Neutropenia – Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
romyelocel-L – Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
TXA-302 – Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
WBI-2100 – Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Chemotherapy Induced Neutropenia – Recent Pipeline Updates 91
Chemotherapy Induced Neutropenia – Dormant Projects 96
Chemotherapy Induced Neutropenia – Discontinued Products 97
Chemotherapy Induced Neutropenia – Product Development Milestones 98
Featured News & Press Releases 98
Sep 09, 2014: Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm 98
May 28, 2014: Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 – A Novel Long-Acting Granulocyte Colony Stimulating Factor to Treat Chemotherapy-induced Neutropenia 98
Mar 25, 2014: Sandoz receives approval for biosimilar filgrastim in Japan 99
Nov 18, 2013: Teva announces Launch of LONQUEX Injection 99
Jul 22, 2013: Zarzio overtakes Neupogen and Granocyte to become most prescribed daily G-CSF in Europe 101
Jun 03, 2013: Teva’s Lonquex Receives Positive Opinion From CHMP For Reduction Of Chemotherapy-induced Neutropenia 101
Apr 25, 2013: Sandoz Files For Marketing Authorization Of Biosimilar Filgrastim In Japan 101
Apr 08, 2013: Spectrum Pharma Initiates Phase II Study Of Long-acting GCSF Drug Candidate SPI-2012 For Treatment Of Chemotherapy-induced Neutropenia 102
Jan 07, 2013: Generon Initiates Phase I/II Clinical Trial Of F-627 For Treatment Of Breast Cancer In China 102
Jun 29, 2012: Teva Pharma Provides Clinical Update On Lipegfilgrastim At MASCC/ISOO 2012 International Symposium On Supportive Care In Cancer 103
Appendix 104
Methodology 104
Coverage 104
Secondary Research 104
Primary Research 104
Expert Panel Validation 104
Contact Us 105
Disclaimer 105

[List of Tables]
Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2014 11
Number of Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Development by Companies, H2 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2014 16
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Development, H2 2014 19
Comparative Analysis by Unknown Stage Development, H2 2014 20
Products under Development by Companies, H2 2014 21
Products under Development by Companies, H2 2014 (Contd..1) 22
Products under Investigation by Universities/Institutes, H2 2014 23
Chemotherapy Induced Neutropenia - Pipeline by Bio-Ker s.r.l, H2 2014 24
Chemotherapy Induced Neutropenia - Pipeline by Biogenomics Limited, H2 2014 25
Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology, Inc., H2 2014 26
Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H2 2014 27
Chemotherapy Induced Neutropenia - Pipeline by Dong-A Socio Group, H2 2014 28
Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2014 29
Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 30
Chemotherapy Induced Neutropenia - Pipeline by Io Therapeutics, Inc., H2 2014 31
Chemotherapy Induced Neutropenia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2014 32
Chemotherapy Induced Neutropenia - Pipeline by Mycenax Biotech Inc., H2 2014 33
Chemotherapy Induced Neutropenia - Pipeline by Myelo Therapeutics GmbH, H2 2014 34
Chemotherapy Induced Neutropenia - Pipeline by Octapharma AG, H2 2014 35
Chemotherapy Induced Neutropenia - Pipeline by PharmaEssentia Corporation, H2 2014 36
Chemotherapy Induced Neutropenia - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2014 37
Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt., H2 2014 38
Chemotherapy Induced Neutropenia - Pipeline by Sandoz Inc., H2 2014 39
Chemotherapy Induced Neutropenia - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 40
Chemotherapy Induced Neutropenia - Pipeline by UAB Profarma, H2 2014 41
Chemotherapy Induced Neutropenia - Pipeline by USV Limited, H2 2014 42
Chemotherapy Induced Neutropenia - Pipeline by Welichem Biotech Inc., H2 2014 43
Chemotherapy Induced Neutropenia - Pipeline by XBiotech USA, Inc., H2 2014 44
Assessment by Monotherapy Products, H2 2014 45
Number of Products by Stage and Target, H2 2014 47
Number of Products by Stage and Mechanism of Action, H2 2014 49
Number of Products by Stage and Route of Administration, H2 2014 51
Number of Products by Stage and Molecule Type, H2 2014 53
Chemotherapy Induced Neutropenia Therapeutics - Recent Pipeline Updates, H2 2014 91
Chemotherapy Induced Neutropenia - Dormant Projects, H2 2014 96
Chemotherapy Induced Neutropenia - Discontinued Products, H2 2014 97

[List of Figures]
Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2014 11
Number of Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Products, H2 2014 19
Assessment by Monotherapy Products, H2 2014 45
Number of Products by Top 10 Targets, H2 2014 46
Number of Products by Stage and Top 10 Targets, H2 2014 46
Number of Products by Top 10 Mechanism of Actions, H2 2014 48
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 48
Number of Products by Top 10 Routes of Administration, H2 2014 50
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 51
Number of Products by Top 10 Molecule Types, H2 2014 52
Number of Products by Stage and Top 10 Molecule Types, H2 2014 53

【掲載企業】

Bio-Ker s.r.l
Biogenomics Limited
Bolder Biotechnology, Inc.
Cellerant Therapeutics, Inc.
Dong-A Socio Group
Generon (Shanghai) Corporation Ltd.
Hanmi Pharmaceuticals, Co. Ltd.
Io Therapeutics, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Mycenax Biotech Inc.
Myelo Therapeutics GmbH
Octapharma AG
PharmaEssentia Corporation
Reliance Life Sciences Pvt. Ltd.
Richter Gedeon Nyrt.
Sandoz Inc.
Teva Pharmaceutical Industries Limited
UAB Profarma
USV Limited
Welichem Biotech Inc.
XBiotech USA, Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆